• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    10/18/23 1:31:08 PM ET
    $AHG
    $ARAV
    $ASMB
    $ATPC
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • SeaStar Medical Holding (NASDAQ:ICU) shares rose 52.9% to $0.69 during Wednesday's regular session. Trading volume for SeaStar Medical Holding's stock is 114.9 million as of 13:30 EST. This is 1614.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.4 million.
    • Streamline Health Solns (NASDAQ:STRM) stock moved upwards by 26.23% to $0.38. As of 13:30 EST, Streamline Health Solns's stock is trading at a volume of 1.2 million, which is 519.9% of its average full-day volume over the last 100 days. The company's market cap stands at $22.3 million.
    • Biocept (NASDAQ:BIOC) shares rose 20.54% to $0.62. Trading volume for Biocept's stock is 5.1 million as of 13:30 EST. This is 264.9% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million.
    • Fresh2 Group (NASDAQ:FRES) shares rose 20.12% to $0.78. The market value of their outstanding shares is at $11.4 million.
    • Harpoon Therapeutics (NASDAQ:HARP) shares rose 19.71% to $6.41. As of 13:30 EST, Harpoon Therapeutics's stock is trading at a volume of 497.7K, which is 1190.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.7 million.
    • Galera Therapeutics (NASDAQ:GRTX) stock increased by 19.16% to $0.24. Galera Therapeutics's stock is trading at a volume of 10.2 million shares as of 13:30 EST. This is 260.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.5 million.

    Losers

    • Aravive (NASDAQ:ARAV) shares decreased by 21.9% to $0.17 during Wednesday's regular session. The current volume of 39.3 million shares is 470.5% of Aravive's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $12.6 million.
    • Generation Bio (NASDAQ:GBIO) shares decreased by 19.94% to $2.49. Trading volume for this security as of 13:30 EST is 2.7 million, which is 2370.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $164.1 million.
    • Assembly Biosciences (NASDAQ:ASMB) shares fell 17.6% to $1.03. As of 13:30 EST, this security is trading at a volume of 6.7 million shares, making up 533.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $54.1 million.
    • Agape ATP (NASDAQ:ATPC) stock declined by 17.03% to $1.17. As of 13:30 EST, this security is trading at a volume of 240.4K shares, making up 17.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $88.2 million.
    • Akso Health Group (NASDAQ:AHG) stock decreased by 16.96% to $1.56. The current volume of 142.8K shares is 78.5% of Akso Health Group's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $35.7 million.
    • Better Therapeutics (NASDAQ:BTTX) shares declined by 15.65% to $0.22. As of 13:30 EST, Better Therapeutics's stock is trading at a volume of 2.9 million, which is 217.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $ARAV
    $ASMB
    $ATPC

    CompanyDatePrice TargetRatingAnalyst
    Generation Bio Co.
    $GBIO
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    Generation Bio Co.
    $GBIO
    12/16/2025$5.00Buy → Hold
    Jefferies
    Assembly Biosciences Inc.
    $ASMB
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    Assembly Biosciences Inc.
    $ASMB
    8/18/2025$50.00Buy
    H.C. Wainwright
    Generation Bio Co.
    $GBIO
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    Assembly Biosciences Inc.
    $ASMB
    3/25/2025$31.00Buy
    Guggenheim
    Assembly Biosciences Inc.
    $ASMB
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    Harpoon Therapeutics Inc.
    $HARP
    1/5/2024$23.00Outperform
    Oppenheimer
    More analyst ratings

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

    Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian's lead product candidate, OBX-115, is a genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of advanced melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer ("NSCLC").Concurrent private placement financing of $350 million expected to fund the combined company into the second half of 2028 and provide capital through multiple clinical data milestones expected in 2027, including NSCLC Phase 1 data (expected 1H 2027) and

    4/14/26 2:08:10 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

    Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian's lead product candidate, OBX-115, is a genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of advanced melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer ("NSCLC"). Concurrent private placement financing of $350 million expected to fund the combined company into the second half of 2028 and provide capital through multiple clinical data milestones expected in 2027, including NSCLC Phase 1 data (expected 1

    4/14/26 8:54:00 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

    Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data  In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ fai

    3/30/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Friedman Michael R.

    4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

    4/9/26 4:39:27 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chang Nancy T

    4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

    4/9/26 4:37:48 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Xie Zhongliang

    3 - Akso Health Group (0001702318) (Issuer)

    4/6/26 9:51:36 PM ET
    $AHG
    Real Estate

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Jefferies with a new price target

    Jefferies downgraded Generation Bio from Buy to Hold and set a new price target of $5.00

    12/16/25 8:41:52 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Assembly Biosciences with a new price target

    Citizens JMP initiated coverage of Assembly Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

    9/24/25 7:55:39 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Assembly Biosciences Inc.

    DEFA14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

    4/22/26 4:22:19 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Assembly Biosciences Inc.

    DEF 14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

    4/22/26 4:12:43 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Galera Therapeutics Inc.

    425 - Galera Therapeutics, Inc. (0001563577) (Subject)

    4/22/26 9:23:41 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

    3/25/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ARAV
    $ASMB
    $ATPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care